Author |
Title |
JournalName |
Year D |
Click on Column Headers to Re-Sort The Current List |
Lopatka JE, Brewerton CN,... |
The protective effects of methysergide, 6-hydroxydopamine and other ag... |
Res Commun Chem Path... |
1976 |
Marquardt GM, DiStefano V... |
Pharmacological and Toxicological Effects of B-3,4-Methylenedioxyamphe... |
Toxicol.Appl.Pharmac... |
1978 |
Johnson MP, Hoffman AJ, N... |
Effects of the enantiomers of MDA, MDMA and related analogues on [3H]s... |
Eur J Pharmacol |
1986 |
Lyon RA, Glennon RA, Tite... |
3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions... |
Psychopharmacology (... |
1986 |
Stone DM, Stahl DC, Hanso... |
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methyl... |
Eur J Pharmacol |
1986 |
Glennon RA, Yousif M, Nai... |
Methcathinone: a new and potent amphetamine-like agent |
Pharmacol Biochem Be... |
1987 |
Battaglia G, Yeh SY, O'He... |
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine de... |
J Pharmacol Exp Ther |
1987 |
Gibb JW, Stone DM, Stahl ... |
The effects of amphetamine-like designer drugs on monoaminergic system... |
NIDA Res Monogr |
1987 |
Steele TD, Nichols DE, Yi... |
Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and... |
Biochem Pharmacol |
1987 |
Gold LH, Koob GF |
Methysergide potentiates the hyperactivity produced by MDMA in rats |
Pharmacol Biochem Be... |
1988 |
Johnson M, Letter AA, Mer... |
Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamp... |
J Pharmacol Exp Ther |
1988 |
Mansbach RS, Braff DL, Ge... |
Prepulse inhibition of the acoustic startle response is disrupted by N... |
Eur J Pharmacol |
1989 |
Nichols DE, Oberlender R,... |
Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA... |
Pharmacol Biochem Be... |
1989 |
Cho AK, Hiramatsu M, Dist... |
Stereochemical differences in the metabolism of 3,4-methylenedioxymeth... |
Drug Metab Dispos |
1990 |
Finnegan KT, Skratt JJ, I... |
The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prev... |
Neurosci Lett |
1990 |
McKenna DJ, Guan XM, Shul... |
3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential eff... |
Pharmacol Biochem Be... |
1991 |
Glennon RA |
Phenylalkylamine stimulants, hallucinogens, and designer drugs |
NIDA Res Monogr |
1991 |
Hiramatsu M, DiStefano E,... |
A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effect... |
Eur J Pharmacol |
1991 |
Johnson M, Bush LG, Gibb ... |
Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in n... |
Eur J Pharmacol |
1991 |
Johnson MP, Huang XM, Nic... |
Serotonin neurotoxicity in rats after combined treatment with a dopami... |
Pharmacol Biochem Be... |
1991 |
McCann UD, Ricaurte GA |
Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not m... |
Brain Res |
1991 |
Yeh SY, Hsu FL |
The neurochemical and stimulatory effects of putative metabolites of 3... |
Pharmacol Biochem Be... |
1991 |
Farfel GM, Vosmer GL, Sei... |
The N-methyl-D-aspartate antagonist MK-801 protects against serotonin ... |
Brain Res |
1992 |
Paulus MP, Geyer MA |
The effects of MDMA and other methylenedioxy-substituted phenylalkylam... |
Neuropsychopharmacol... |
1992 |
Monte AP, Marona-Lewicka ... |
Synthesis and pharmacological examination of benzofuran, indan, and te... |
J Med Chem |
1993 |
Miller DB, O'Callaghan JP |
Environment-, drug- and stress-induced alterations in body temperature... |
J Pharmacol Exp Ther |
1994 |
O'Callaghan JP, Miller DB |
Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mou... |
J Pharmacol Exp Ther |
1994 |
Hegadoren KM, Martin-Iver... |
Comparative behavioural and neurochemical studies with a psychomotor s... |
Psychopharmacology (... |
1995 |
Sprague JE, Nichols DE |
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-meth... |
J Pharmacol Exp Ther |
1995 |
Miller RT, Serrine SL, Mo... |
Metabolism of 5-(Glutathion-S-yl)-a-methyldopamine Following Intracere... |
Chem Res Toxicol |
1995 |
Miller RT, Lau SS, Monks ... |
Effects of intracerebroventricular administration of 5-(glutathion-S-y... |
Chem Res Toxicol |
1996 |
Finnegan KT, Taraska T |
Effects of glutamate antagonists on methamphetamine and 3,4-methylened... |
J Neurochem |
1996 |
Chu T, Kumagai Y, DiStefa... |
Disposition of methylenedioxymethamphetamine and three metabolites in ... |
Biochem Pharmacol |
1996 |
Miller DB, O'Callaghan JP |
Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interac... |
Ann N Y Acad Sci |
1996 |
Miller RT, Lau SS, Monks ... |
2,5-bis-(Glutathion-S-yl)-alpha-methyldopamine, a putative metabolite ... |
Eur J Pharmacol |
1997 |
Kombian SB, Saleh TM, Fia... |
Ibogaine and a total alkaloidal extract of Voacanga africana modulate ... |
Brain Res Bull |
1997 |
Lindefors N, Barati S, O'... |
Differential effects of single and repeated ketamine administration on... |
Brain Res |
1997 |
Kankaanpaa A, Meririnne E... |
The acute effects of amphetamine derivatives on extracellular serotoni... |
Pharmacol Biochem Be... |
1998 |
Bai F, Lau SS, Monks TJ |
Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine pr... |
Chem Res Toxicol |
1999 |
Arvanov VL, Liang X, Russ... |
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA recepto... |
Eur J Neurosci |
1999 |
Schatz DS, Kaufmann WA, S... |
3,4-Methylenedioxymetamphetamine (ecstasy) induces c-fos-like protein ... |
Synapse |
2000 |
Shirayama Y, Hashimoto K,... |
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA i... |
Eur J Pharmacol |
2000 |
Mansvelder HD, McGehee DS |
Long-term potentiation of excitatory inputs to brain reward areas by n... |
Neuron |
2000 |
Bai F, Jones DC, Lau SS, ... |
Serotonergic Neurotoxicity of 3,4-(+/-)-Methylenedioxyamphetamine and ... |
Chem Res Toxicol |
2001 |
Russell BR, Laverty R |
The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-in... |
Pharmacology, Bioche... |
2001 |
O'Loinsigh ED, Boland G, ... |
Behavioural, hyperthermic and neurotoxic effects of 3,4- methylenediox... |
Prog Neuropsychophar... |
2001 |
Baumann MH, Pablo J, Ali ... |
Comparative neuropharmacology of ibogaine and its O-desmethyl metaboli... |
Alkaloids Chem Biol |
2001 |
Carvalho M, Hawksworth G,... |
Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vi... |
Arch Toxicol |
2002 |
Lebsanft HB, Mayerhofer A... |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unila... |
J Neural Transm |
2003 |
Easton N, Fry J, O'Shea E... |
Synthesis, in vitro formation, and behavioural effects of glutathione ... |
Brain Res |
2003 |
Carvalho M, Milhazes N, R... |
Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopami... |
Arch Toxicol |
2003 |
Narendran R, Frankle WG, ... |
Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketam... |
Am J Psychiatry |
2005 |
Capela JP, Macedo C, Bran... |
Neurotoxicity mechanisms of thioether ecstasy metabolites |
Neuroscience |
2007 |
Litjens RP, Brunt TM |
How toxic is ibogaine? |
Clin Toxicol (Phila) |
2016 |
Wallach J, Kang H, Colest... |
Pharmacological Investigations of the Dissociative 'Legal Highs' Diphe... |
PLoS One |
2016 |
Kang H, Park P, Bortolott... |
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor ... |
Neuropharmacology |
2017 |
Ingram R, Kang H, Lightma... |
Some distorted thoughts about ketamine as a psychedelic and a novel hy... |
Neuropharmacology |
2018 |
Botanas CJ, de la Peņa JB... |
Methoxetamine: A foe or friend? |
Neurochem Int |
2019 |